Combinations of FGFR4 inhibitors and bile acid sequestrants

Patent metadata

Field	Value
Publication number	US-11229643-B2
Application number	US-201716347194-A
Country	US
Kind code	B2
Filing date	Nov 1, 2017
Priority date	Nov 2, 2016
Publication date	Jan 25, 2022
Grant date	Jan 25, 2022

Abstract

The present invention relates to a pharmaceutical combination comprising an FGFR4 inhibitor and a bile acid sequestrant, to the use of the pharmaceutical combination in the treatment of cancer, to the use of a bile acid sequestrant to reduce or mitigate side-effects associated with FGFR4 inhibition therapy.

First claim

What is claimed:

1. A method of reducing side effects associated with FGFR4 inhibitor therapy, wherein the side effects comprise the increase of
(a) liver enzyme in the serum, plasma or blood of the subject taking FGFR4 inhibition therapy, wherein the liver enzyme comprises alanine aminotransferase, or
(b) miRNA122 in the subject taking FGFR4 inhibition therapy,
wherein the FGFR4 inhibition therapy is for the treatment of liver cancer and the FGFR4 inhibition therapy comprises administration of an FGFR4 inhibitor which comprises N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide;

and
a bile acid sequestrant.

2. A pharmaceutical combination for the treatment of liver cancer comprising N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide in free form or in pharmaceutically acceptable salt form, and a bile acid sequestrant.

3. The pharmaceutical combination according to claim 2 , wherein the FGFR4 inhibitor is N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide in citric acid salt form.

4. The method of claim 1 , wherein the bile acid sequestrant is selected from cholestyramine, colesevelam, colesevalam hydrochloride, colestipol or selevamer.

5. The pharmaceutical combination according to claim 2 , wherein the bile acid sequestrant is cholestyramine.

6. The method of claim 1 , wherein the side effects associated with FGFR4 inhibition therapy are side effects associated with treatment of liver cancer, wherein the FGFR4 inhibitor is N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide in citric acid salt form, and wherein the side effects associated with treatment of liver cancer do not include diarrhea.

7. The method of claim 1 , wherein the bile acid sequestrant is cholestyramine.

8. A method for reducing side effects associated with FGFR4 inhibition therapy in a subject, the method comprising simultaneously or sequentially administering to the subject cholestyramine and an FGFR4 inhibitor comprising N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide in citric acid salt form.

9. The method of claim 8 , wherein the FGFR4 inhibition therapy is for the treatment of liver cancer.

10. A method for reducing side effects associated with FGFR4 inhibition therapy in a subject afflicted with liver cancer, the method comprising simultaneously or sequentially administering to the subject an FGFR4 inhibitor for the treatment of liver cancer and a bile acid sequestrant, wherein the side effects comprise the increase of
(a) liver enzymes in the serum, plasma or blood of the subject taking FGFR4 inhibition therapy, wherein the liver enzyme compromises alanine aminotransferase, or
(b) miRNA122 in the subject taking FGFR4 inhibition therapy,
wherein the FGFR4 inhibitor is N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide in free form, in pharmaceutically acceptable salt form or in citric acid form.

11. The method of claim 10 , wherein the bile acid sequestrant is cholestyramine.

12. The method of claim 10 , wherein the bile acid sequestrant is selected from cholestyramine, colesevelam, colesevalam hydrochloride, colestipol or selevamer.

Assignees

• Novartis Ag

Inventors

• Fairhurst Robin Alec
• Graus Porta Diana
• Kinyamu-Akunda Jacqueline
• Mahl Andreas Joerg
• Manenti Luigi
• Weiss Andreas
• Wolf Armin
• Wuersch Kuno

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61K31/506 Primary

  not condensed and containing further heterocyclic rings · CPC title

• A61K31/4545 Primary

  containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine · CPC title

• A61K2300/00

  Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00 · CPC title

• A61K31/496 Primary

  Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin · CPC title